OSI-906
Catalog No. A11053
OSI-906是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。
- Masao Kakoki, .et al. Cyanocobalamin prevents cardiomyopathy in type 1 diabetes by modulating oxidative stress and DNMT-SOCS1/3-IGF-1 signaling, Communications Biology, 2021, 4:775
- Nakamura T, .et al. Naturally Occurring Hair Growth Peptide: Water-Soluble Chicken Egg Yolk Peptides Stimulate Hair Growth Through Induction of Vascular Endothelial Growth Factor Production, J Med Food, 2018, Jul;21(7):701-708 PMID: 29583066
- Tzeng SF, .et al. O-Glycosylation-mediated signaling circuit drives metastatic castration-resistant prostate cancer, FASEB J, 2018, Jun 15:fj201800687 PMID: 29906246
- Takata N, .et al. IGF-2/IGF-1R signaling has distinct effects on Sox1, Irx3, and Six3 expressions during ES cell derived-neuroectoderm development in vitro, In Vitro Cell Dev Biol Anim., 2016, May;52(5):607-15 PMID: 26956358
Catalog Num | A11053 |
---|---|
M. Wt | 421.5 |
Formula | C26H23N5O |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 867160-71-2 |
Synonyms | OSI906, linsitinib |
SMILES | CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O |
OSI-906是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。
Targets
Target | Value |
---|---|
IGF-1R | IC50: 35nM |
Insulin Receptor | IC50: 75nM |
IRR | IC50: 75nM |
Abl | IC50: >10μM |
ALK | IC50: >10μM |
BTK | IC50: >10μM |
EGFR | IC50: >10μM |
EphA1 | IC50: >10μM |
EphB1 | IC50: >10μM |
FES | IC50: >10μM |
FGFR1 | IC50: >10μM |
FGFR2 | IC50: >10μM |
Fyn | IC50: >10μM |
PKA | IC50: >10μM |
PKCα | IC50: >10μM |
ROCK1 | IC50: >10μM |
IRAK4 | IC50: >10μM |
JAK2 | IC50: >10μM |
KDR | IC50: >10μM |
LCK | IC50: >10μM |
LynA | IC50: >10μM |
LynB | IC50: >10μM |
Met | IC50: >10μM |
TrkA | IC50: >10μM |
PDGFRα | IC50: >10μM |
PDGFRβ | IC50: >10μM |
FAK | IC50: >10μM |
BRK | IC50: >10μM |
RET | IC50: >10μM |
Pim1 | IC50: >10μM |
CDK1 | IC50: >10μM |
DYRK2 | IC50: >10μM |
Src | IC50: >10μM |
Tek | IC50: >10μM |
MEK1 | IC50: >10μM |
Akt1 | IC50: >10μM |
Akt2 | IC50: >10μM |
AuroraA | IC50: >10μM |
AuroraB | IC50: >10μM |
PDK-1 | IC50: >10μM |
PLK1 | IC50: >10μM |
p38α | IC50: >10μM |
ERK1 | IC50: >10μM |
GSK-3α | IC50: >10μM |
p70S6K | IC50: >10μM |
In vitro (25°C) | DMSO | 80 mg/mL (189.8 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 5%DMSO+40%PEG300+5%Tween80+50%ddH2O | 5.93 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 23.72 mL | 118.62 mL | 237.25 mL |
0.5 mM | 4.74 mL | 23.72 mL | 47.45 mL |
1 mM | 2.37 mL | 11.86 mL | 23.72 mL |
5 mM | 0.47 mL | 2.37 mL | 4.74 mL |
*The above data is based on the productmolecular weight 421.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.